Navigation Links
Max Neeman International ISO 14155: 2011 Certified for Medical Device Trials
Date:9/28/2011

RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2011 /PRNewswire/ -- Max Neeman announces the grant of ISO 14155:2011 certificate; the only Indian CRO and one of only a few global CROs to be certified for design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety or performance of medical devices for regulatory purposes.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Max Neeman has formed an experienced team of medical device experts specializing in carrying out Cardiac, CNS, Ophthalmology and various other device therapeutic trials and ISO 14155 certification establishes standards to harmonize these trials ensuring safety, effectiveness, performance and quality. The company is part of the 'Max India Group' also consisting of Max Healthcare, which owns and manages a leading cardiovascular institute among its 13 hospitals.

The ISO 14155:2011 certification Max Neeman has achieved, specifies general requirements intended to protect the rights, safety and well-being of human subjects, ensure the scientific conduct of the clinical investigation and the credibility of the results, define the responsibilities of the sponsor and principal investigator, and assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

With India's device market currently being valued at US $1.7 Billion and projected to grow at the rate of 23% annually, India is fast emerging as a destination of choice for medical device development and conducting device trials.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is also an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President USA for more information at +1.919.424.3345 / donald.swankie@neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
6. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
7. Max Neeman Develops Innovative Approach for Rare Disease Studies
8. Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
Breaking Medicine Technology:
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... Illinois (PRWEB) , ... May 26, 2017 , ... Silver ... The community, which is located on more than four acres of land at 5620 ... independence. , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... ... ... Happened in the Garden of Eden”: retells the stories of three Bible figures in modern ... author, Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born ... At six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Medical Center CEO Mary Ellen, hospital employees, and town officials to celebrate the ... The facility was developed by Rendina as part of its ongoing relationship with ...
Breaking Medicine News(10 mins):